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Abstract
Background: Infants born <29 weeks gestation are at high risk of neurocognitive disability. Early postnatal growth
failure, particularly head growth, is an important and potentially reversible risk factor for impaired
neurodevelopmental outcome. Inadequate nutrition is a major factor in this postnatal growth failure, optimal
protein and calorie (macronutrient) intakes are rarely achieved, especially in the first week. Infants <29 weeks are
dependent on parenteral nutrition for the bulk of their nutrient needs for the first 2-3 weeks of life to allow gut
adaptation to milk digestion. The prescription, formulation and administration of neonatal parenteral nutrition is
critical to achieving optimal protein and calorie intake but has received little scientific evaluation. Current neonatal
parenteral nutrition regimens often rely on individualised prescription to manage the labile, unpredictable
biochemical and metabolic control characteristic of the early neonatal period. Individualised prescription frequently
fails to translate into optimal macronutrient delivery. We have previously shown that a standardised, concentrated
neonatal parenteral nutrition regimen can optimise macronutrient intake.
Methods: We propose a single centre, randomised controlled exploratory trial of two standardised, concentrated
neonatal parenteral nutrition regimens comparing a standard macronutrient content (maximum protein 2.8 g/kg/
day; lipid 2.8 g/kg/day, dextrose 10%) with a higher macronutrient content (maximum protein 3.8 g/kg/day; lipid
3.8 g/kg/day, dextrose 12%) over the first 28 days of life. 150 infants 24-28 completed weeks gestation and
birthweight <1200 g will be recruited. The primary outcome will be head growth velocity in the first 28 days of
life. Secondary outcomes will include a) auxological data between birth and 36 weeks corrected gestational age b)
actual macronutrient intake in first 28 days c) biomarkers of biochemical and metabolic tolerance d) infection
biomarkers and other intravascular line complications e) incidence of major complications of prematurity including
mortality f) neurodevelopmental outcome at 2 years corrected gestational age
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The risk of significant neurocognitive disabilities in pre-
term survivors is well recognised, particularly under 26
weeks gestation [1,2]. Although many factors are asso-
ciated with an increased risk of neurocognitive impair-
ment, postnatal growth failure is now recognized as an
important and potentially reversible risk [3-5]. Subopti-
mal growth is common in very low birthweight infants
(VLBWI) [6,7] especially in those under 26 weeks [8].
Head growth is an especially important measure of
growth failure because it correlates with brain growth
[9]. Hack et al showed that subnormal head size at 8
months was predictive of poorer verbal and performance
IQ scores at 3 [10] and 8 years [11]. Brain growth by 28
days after birth and the expected date of delivery are
key predictors of long-term brain growth [12,13].
Early postnatal growth failure or extrauterine growth
restriction describes the severe nutritional deficit that
develops in preterm infants in the first few weeks of life
[3,4]. The deficit refers to the gap between the energy
and protein (and other nutrients) required to mimic
fetal growth rates and the energy and protein that is
actually delivered to the preterm infants. Current
recommendations suggest a calorie intake of 120kcal/kg/
d a ya n dam i n i m a lp r o t e i ni n t a k eo f2 . 5 - 3g / k g / d a y .
These are estimates based on matching fetal growth in
utero [14] but do not take into account other factors
that may increase individual infant requirements (such
as catch-up growth, sepsis and chronic respiratory dis-
ease) and therefore increase the risk of postnatal growth
failure [15]. Indeed, postnatal malnutrition may be inevi-
table based on current recommendations [16,17] and is
exacerbated by huge variations in neonatal nutritional
practice [18-21].
Very preterm infants have a gut that is too immature
to digest milk in sufficient quantity to meet nutritional
requirements. Virtually all preterm infants <29 weeks
gestation and <1200 g require parenteral nutrition (PN)
for a period that depends on gestation birthweight and
other morbidities. The mean duration of PN (>75% all
nutrition) in these infants (survivors) is 15.6 days [17]
increasing to 20.8 days for infants <700 g [6]. Given
these infants have the highest incidence of early and late
growth failure and long term neurocognitive disability,
effective PN delivery is essential to avoid major early
nutritional deficits in these infants.
Inadequate and/or inconsistent nutritional strategies
are one barrier to effective PN delivery but there are
others. The most important is metabolic “intolerance”.
Early concerns about amino acid tolerance [22] continue
to have profound effects on nutritional policies [23].
More recent evidence evaluating neonatal amino acid
PN formulations, suggests amino acids can be rapidly
introduced without metabolic complications [24-28]
even in sick infants [29] and without causing acidosis
[30]. This is essential if fetal protein accretion rates are
to be matched and the large protein deficits which are
routinely encountered in the first week of life are to be
avoided [31]. Recommended maximum protein intake is
4 g/kg/day [31].
Optimal utilisation of protein for preterm infant
growth depends on an adequate non-protein energy
intake. A minimum of 20-25kcal/g protein is required
[22,32] indicating that 100-120kcal/kg/day is needed to
achieve maximal protein accretion [33]. Glucose and
lipid infusion rates needed to achieve this may not be
tolerated, especially in the first week, leading to hyper-
glycaemia and hyperlipidaemia. Increasing protein intake
without providing an adequate non-protein calorie
intake may result in growth failure and increased blood
levels of urea and amino acids [34]. Carbohydrate may
be the major determinant of optimal growth in preterm
infants [35] and should account for 60-75% calories
[31]. Glucose intolerance can be managed with reducing
intake but is routinely managed effectively with an insu-
lin infusion [36,37] although the long term risks and
benefits of this approach are still unknown.
Postnatal growth can be improved with increased
macronutrient intake [38-40] but evidence for an effect
long-term neurodevelopment is more limited. Early
introduction of amino acids [41] can also improve short
term postnatal growth but in this study [41], persistent
differences in head circumference did not translate into
altered neurodevelopment outcome. Tan et al [17] did
not show improved neurodevelopmental outcome with
increased macronutrient int a k eb u td i dn o ta c h i e v et h e
differences in nutritional intake expected. A correlation
between protein and energy deficit (first 28 days) head
growth at 36 weeks CGA was demonstrated and energy
deficit (28 days) was associated with worse neurodeve-
lopmental outcome at 3 months [42]. Early nutritional
intake of a cohort of extremely low-birthweight survi-
vors [43] has been correlated with 18 month neurodeve-
lopmental outcomes. This suggested that early head
growth failure may have a lasting effect on neurocogni-
tive ability even if there was subsequent catch up growth
before term. Provisional reports from other population-
based cohort studies have supported this association
[44] suggesting a change in head circumference z-score
of -1.4 between birth and 28 days. This is consistent
with our own audit findings and those of Tan et al
(unpublished data) suggesting head growth failure
reaches a nadir at approximately day 28. However, evi-
dence linking early nutritional intervention with
improved early head (and then ultimately neurodevelop-
mental outcome) is still lacking.
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in the very preterm infant are PN prescription, formu-
lation and administration. The conventional neonatal
PN strategy has been based on individualised neonatal
PN (iNPN) prescription and formulation to address the
rapidly changing and variable fluid and electrolyte
needs characteristic of the very preterm infant. This
can be at the expense of early nutritional strategy
when the evidence base supports early and consistent
macronutrient delivery. Poor neonatal PN prescribing
practice contributes to poor nutrition [45,46] and com-
puter aided prescribing [47] can improve protein and
energy intake [48,49]. However, iNPN has other
limitations. Although iNPN prescription is flexible, the
manufactured individualized PN bag is not so rapid
responses to changes in fluid and electrolyte require-
ments after manufacture is not possible. When Tan et
al [17] compared 2 iNPN regimens with a 30%
difference in prescribed macronutrient content, the dif-
f e r e n c ei na c t u a le n e r g ya n dp r o t e i ni n t a k ew a s< 1 5 % .
This inefficiency in PN delivery was due to co-
administration of other drug infusions, fluid restriction
and changing electrolyte requirements. Thus, maximis-
ing nutritional intake in very preterm infants cannot
be guaranteed by simply increasing the macronutrients
in the PN formulation.
Standardising neonatal PN has been considered as an
alternative to iNPN regimens [50] but has receive scant
attention in published guidelines [31,51]. Early evidence
suggested iNPN was required to meet the complex of
the preterm infant [37]. Although some recent studies
concur [49,52] increasing evidence suggests that with
careful attention to local workload and PN prescribing
practice most infants can be managed on a standard PN
formulation [53-60] sometimes with improved macronu-
trient intake. Standardised PN solutions that allow some
flexibility with electrolytes can overcome the variability
in preterm electrolyte needs [56]. Increasing the concen-
tration of neonatal PN (reducing the volume) has the
potential to maintain nutritional intake in the face of
fluid restriction and multiple drug infusions. Conven-
tionally, stability and osmolality concerns have limited
this approach, but current guidelines have virtually no
evidence base. High osmolality of aqueous PN solutions
can be offset by concurrent administration of intrave-
nous lipids and dextrose.
Using the standardisation and concentration concepts,
the preterm infant’s competing needs for extreme flexibil-
ity for fluid and electrolyte management versus consistent
optimal nutritional delivery can be accommodated in a
“two compartment” PN model. We developed a standar-
dised concentrated neonatal PN (scNPN) regimen that
comprised a relatively inflexible (protected) nutrition com-
partment (85 ml/kg/day aqueous PN and 15 ml/kg/day
intravenous lipid) and a highly flexible supplementary
fluid compartment (usually 50 ml/kg/day). This supple-
mentary compartment is then reduced or increased as
total fluid requirements demand. Unexpected electro-
lyte derangement is corrected using standardised elec-
trolyte infusions that replace part of the supplementary
infusion as required. All standardized drug infusions
are managed in the same way. Changes in infusion rate
are titrated against the supplementary infusion not the
nutrition compartment. Finally, early introduction of
enteral feeds results in the reduction of the supple-
mentary infusion until the enteral feed rate exceeds
the supplementary infusion rate. Only then is PN
reduced. This system allows maximum flexibility of
fluid, electrolyte and drug infusion management with
minimal impact on nutrient delivery.
We have shown the scNPN system of PN delivery is
more effective at delivering protein, with >90% infants
receiving >90% prescribed protein [60]. This lead to a
20% increase in the first 14 day protein intake when
compared to a nutritionally identical iNPN regimen
[60]. Significant cost reductions were also achieved
(38%) similar to those reported for other standardised
regimens [57]. There are no randomised controlled
trials comparing standardised versus individualised
neonatal PN, probably because logistics and patient
safety considerations make this unfeasible in the
complex very preterm population. However, given the
potential benefits of the scNPN, a randomised con-
trolled trial comparing the existing scNPN regimen
with one where macronutrient content was maximised
(scNPNmax) is desirable.
Hypothesis
We speculate that the scNPN and scNPNmax regimens
will provide efficient macronutrient delivery in the early
neonatal period. We propose that optimising early pro-
tein and energy intake will partially correct early head
growth failure characteristic of infants <29 weeks
gestation. This could have implications for long term
neurodevelopment. We hypothesise that the 30% increase
in protein and calories achieved by the scNPNmax regi-
men will lead to a significant improvement in head
growth velocity over the first 28 days of life.
Primary objective
To compare the two allocation groups with respect to
the rate of head growth from measurement made at
enrolment to a measurement made between 27 and 29
completed days after birth (i.e. change in head circum-
ference/(time of last measurement-time of first
measurement)
Secondary objectives
To compare the two allocation groups with respect to
the following:
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at 36 weeks corrected gestational age (CGA):
- occipitofrontal head circumference (OFC), weight,
mid-upper arm circumference (MUAC) and lower
leg length (LLL)
- modelling of weekly head growth, protein and
calorie intake data
b) the efficiency of nutrient delivery (including proto-
col violations).
Nutritional intake at 7, 14, 21 and 28 days
- energy, protein, fat, glucose (including energy and
protein deficits)
- predicted iNPN intakes based on mathematical
model
c) the tolerance to each regimen by identifying
abnormalities (and any required clinical interventions)
in the following:
Nutritional tolerance (first 28 days or duration of PN):
- protein: daily serum urea, metabolic acidosis,
amino acid profile day 7 and 21.
- fat: weekly triglyceride profile, hyperlipidaemia
- glucose: hypo/hyperglycaemia (including insulin
use)
Biochemical tolerance (first 28 days or duration
of PN):
- serum electrolytes, bone biochemistry and liver
function
Use of supplementary electrolyte infusions
d) other recognised PN complications
Vascular access device usage and non-infective
complications
- Vascular access device complications including
extravasation injury
Infection:
- number of positive blood cultures
- number of infection and suspected infection
episodes
e) Major neonatal morbidity
- Necrotising enterocolitis or focal intestinal
perforation
- Chronic lung disease
- Intracranial abnormality on cranial ultrasound scan
or other imaging
- Pulmonary haemorrhage
- Patent ductus arteriosus
- Retinal surgery
f) Neurodevelopmental outcome at 2 years (assessed
using Bayley III scales)
Methods/Design
Trial design
A single centre, parallel group, randomised controlled
trial with blinding of parents and outcome assessors.
The control group will receive the standardised, concen-
trated neonatal parenteral nutrition formulation
(scNPN) used in current clinical practice and the
intervention group will receive a similar formulation
containing additional macronutrients (scNPNmax).
Ethical and regulatory approval
Ethical approval was confirmed in May 2009 (09/H1008/
91) by the Central Manchester REC (UK). Medicines
and Healthcare products Regulatory Agency (MHRA)
approval was given in May 2009.
Inclusion criteria
Infants born 24
+0-28
+6 weeks gestation who weigh
<1200 g and who are admitted to the Neonatal Unit at
Liverpool Women’s Hospital within 48 hours of birth.
Exclusion criteria
a) Infants who are unlikely to survive the first week after
birth.
b) Infants diagnosed with major congenital or chro-
mosomal abnormalities known to affect gastrointestinal
function
c) Infants diagnosed with major congenital or chromo-
somal abnormalities known to affect head growth
including definite parenchymal lesions on cranial ultra-
sound scan in first 48 hours.
d) Parents who are unable to give informed consent
Eligibility and consent
Eligible patients will be identified from the electronic
patient data management system by the Investigator.
The parent/guardian(s) of each potentially eligible
patient will be approached when the baby has achieved
respiratory and haemodynamic stability, usually at
approximately 48 hours. When clinical circumstances
permit the parents of a potentially eligible baby will be
approached before birth. The Investigator will explain
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using the Patient Information Leaflet. The parents will
have a minimum of 2 hours to consider the study but
study information can be considered for a period up to
120 hours from birth.
Randomisation
Where feasible, randomisation should occur before 72
hours of age where possible but must occur within 120
hours. Randomization codes will be computer generated
using the statistical package STATA. Once generated
the randomisation lists will be sealed in opaque serially
numbered envelopes and given to pharmacy to store in
a secure place. The randomisation list will be stratified
by gestation at birth: 24-26 and 27-28 completed weeks
gestation at birth. Once a patient is consented in to the
trial, pharmacy will open the next sequential envelope
in the correct strata and provide the allocated interven-
tions. Allocation concealment will be maintained except
in the Pharmacy Department at Liverpool Women’s
Hospital. In the case of multiple births, each infant will
be individually randomised.
Subject withdrawal
Patients may be withdrawn if the parent(s)/guardian(s)
withdraws consent. Following withdrawal patients will
be managed according to usual clinical practice. This
means the patient will receive scNPN and routine
biochemical and growth monitoring. Parents will be
asked whether or not they consent to trial-related data
t ob ec o l l e c t e df o rt h e i rb a b y ( i e s )a n dw h e t h e ro rn o t
they consent to the continued use of information that
has already been collected about their child.
Occasionally, infants on PN can become metabolically
unstable (as determined by routine biochemical moni-
toring). This is usually managed by stopping or reducing
PN and then gradually reintroducing PN once things
improve. If such improvement is not sustained then an
independent clinician and biochemist will discuss the
need for possible withdrawal from the trial.
Blinding
The manufacture and labelling of scNPN and scNPNmax
will take place at the Department of Pharmacy, Aseptic
Manufacturing Unit, Royal Liverpool and Broadgreen
University Hospitals NHS Trust (RLBUHT). This will
allow Pharmacy at Liverpool Women’s Hospital (LWH)
to allocate the correct treatment according to randomi-
sation while ensuring the final presentation of parenteral
nutrition at the cotside will be in a form that does not
reveal treatment allocation. Similarly, none of the pre-
scription charts or documentation will indicate treat-
ment allocation. This will effectively blind parents, most
clinicians involved in patient care and individuals
assessing study end-points. It will be possible for the
prescriber (and the neonatal nurse or any other clinical
person checking the prescription) to recognise different
treatment allocations during the prescribing and admin-
istration process. This system ensures the safe prescrip-
tion of PN using the existing robust supervisory
framework. The Pharmacy Department at Liverpool
Women’s Hospital will record treatment allocation and
will be able to “break the code” if a serious adverse
event occurs, or at the request of the DMEC.
Record of study participation
I na c c o r dw i t hR & Dp o l i c ya tL W H ,t h en o t e so fa l l
participants will be marked with a sticker (notes) or
a"tag” (electronic records). All clinical records of study
participants will be retained for 20 years. All paper and
electronic records relating to the study will be retained
for 20 years.
Methods: Treatment Regimen
Study parenteral nutrition
Neonatal PN is manufactured under EU Good Manufac-
turing Practice at the Department of Pharmacy, Aseptic
Manufacturing Unit, Royal Liverpool and Broadgreen
University Hospitals NHS Trust (RLBUHT). The scNPN
formulation is constituted according to the policy for
Neonatal Parenteral Nutrition at Liverpool Women’s
Hospital the dispensing pharmacy will oversee the treat-
ment allocation and the dispensing of study PN. The
scNPNmax is manufactured using the same policy gui-
dance and differs only in the macronutrient content.
This study will compare two standardised concen-
trated neonatal PN regimens. The current standardised,
concentrated formulation of PN (scNPN) together with
a system of fluid and electrolyte management that
allows effective nutritional delivery will comprise the
control group. The intervention group will receive
scNPNmax.T h es c N P N max regimen follows the same
administration protocol as the scNPN regimen but has a
greater macronutrient content (Table 1). The other
Table 1 Comparison between scNPN and scNPNmax
macronutrient content and PN fluid volumes in a total
fluid volume of 150 ml/kg/day
PN component scNPN scNPNmax
Maximum protein (g/kg/day) 2.8 3.8
Maximum lipid (g/kg/day) 2.8 3.8
Maximum glucose (g/kg/day) 13.5 15.6
Total calorie intake (kcal/kg/day) 85 103
Maximum aqueous PN volume (ml/kg/day) 85 100
Maximum intravenous lipid volume (ml/kg/day) 15 20
Maximum supplementary dextrose volume
(ml/kg/day)
50 30
Morgan et al. BMC Pediatrics 2011, 11:53
http://www.biomedcentral.com/1471-2431/11/53
Page 5 of 11components of the scNPNmax regimen are identical to
that of scNPN. Thus, 3 nutritionally identical aqueous
PN bags, MAX1 (no electrolytes), MAX2 (maintenance
electrolytes for preterm infants) and MAX3 (MAX2
with additional sodium) cater for the different electro-
lyte requirements as described above for STD1, STD2
and STD3. The levels of macronutrient present in
scNPNmax fall within international recommendations
[31] and are consistent with those studies providing the
evidence for early, aggressive nutritional strategies [3,4].
Description, labelling and storage of PN
The pharmacy at Liverpool Women’sH o s p i t a l( L W H )
and the Pharmacy Aseptic Manufacturing Unit at the
RLBUHT will coordinate the provision of study scNPN
and scNPNmax to ensure there is sufficient and appro-
priate supply to all patients in the study. The pharmacy
at Liverpool Women’s Hospital and the Pharmacy Asep-
tic Manufacturing Unit at the RLBUHT will be respon-
sible for tracking the allocation of all trial-related
materials.
PN will be presented as:
a) a bag containing the aqueous PN components.
During manufacture
- bags for the scNPN regimen will be labelled as
STD1, STD2, STD3
-b a g sf o rt h es c N P N max regimen will be labelled
as MAX1, MAX2, MAX3
b) a syringe containing intralipid
c) a syringe containing supplementary dextrose
infusion
Administration
The administration of scNPN (or scNPNmax) will follow
the current LWH NICU PN administration guidelines
and will not differ from PN administration in infants
not in the study (these infants will all receive scNPN).
Following birth, scNPN will be administered until con-
sent is obtained and the patient randomised to receive
either scNPN or scNPNmax. In accordance with the PN
guidelines, PN administration will continue until the
child is on 75% enteral feeds. If enteral feeds are
stopped or markedly reduced (<25% total intake) after
this point and the infant is <28 days, the original study
PN will be restarted as soon as practical. If feeds are
reduced but still exceed 25% total, study PN will be
reintroduced only if enteral feeding <75% persists for
more than 24 hours. All infants who need PN after 28
days will be prescribed scNPN. The introduction of PN,
PN infusion rates (including the management of supple-
mentary infusions) and reduction of PN with increased
enteral feeds are described in detail in LWH NICU PN
guidelines.
Intolerance and over-dosage
The ability of individual infants to tolerate different PN
components varies greatly, with age, gestation and clini-
cal condition all contributing. This unpredictability
requires regular and frequent biochemical monitoring
described in LWH NICU PN guidelines. Clinicians and
pharmacists will monitor PN tolerance and make neces-
sary adjustments to PN administration as determined by
daily clinical information and biochemical monitoring.
Assessment of compliance with study PN
The amount prescribed is not necessarily the amount
that a baby receives. Effectiveness of PN delivery is a
secondary outcome for this study. Detailed and compre-
hensive information about the amount of PN infused is
collected in the medical record. This will be transcribed
to the CRF. This will allow accurate calculation of actual
daily PN administration to individual patients. The
results of these calculations will be recorded on the
CRF. Expected daily PN is also recorded in the medical
record. This will allow identification of any major
deviation (>15 ml/kg/day) from the LWH guidelines.
Non-trial PN will be administered until the infant is
randomised. Following randomisation, administration of
the non-trial PN/fluids may occasionally occur (eg
severe hypoglycaemia, transfer to operating theatre or
another centre). Administration of non-trial PN/fluids
will still be fully recorded to allow full nutritional for
the first 28 days to be calculated.
Concomitant medications/treatments
These will be administered to all patients in accordance
with the existing LWH PN guidelines and LWH NICU
drug formulary. The study will not affect the use of
concomitant medications/treatments.
Methods: Assessments and Procedures
Study schedule
The study schedule is summarised in Table 2. Randomi-
sation will occur within 120 hours of birth. Following
randomisation, baseline growth measurements will be
performed. The study PN will be introduced at the ear-
liest opportunity following randomisation. The process
of collecting large amounts of routine monitoring data
has been evaluated and refined in a previous study [51]
Intravenous/enteral nutrition, fluid and drug infusion data
T h eh o u r l yv o l u m eo fe a c hc o m p o n e n to ft h ei n t r a v e -
nous/enteral nutrition, fluida n dd r u gi n f u s i o n si sc a p -
tured on routine nursing charts. Each 24 hour period
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for 28 completed days after birth.
Biochemical/nutritional monitoring
Biochemical and nutritional monitoring will follow the
protocol outlined in the LWH NICU PN guidelines
(incorporated in the study schedule summary in
Appendix 1).
Growth monitoring
Occipitofrontal head circumference, weight, mid-upper
arm circumference and lower leg length will be mea-
sured after 7, 14, 21, 28 days and then weekly until 36
weeks CGA.
Infection monitoring
Monitoring for infection will follow the protocol out-
lined in the LWH NICU guidelines for infection. Daily
CRP, white cell count (and neutrophils) and platelet
data will be recorded in medical record and transcribed
to the appropriate CRF for 35 days from birth.
Line complications
Vascular access device usage and location data will be
recorded including extravasation episodes resulting in
skin/tissue injury.
Neurodevelopmental follow-up
Following discharge, infants of this gestation have
routine, out-patient, neurodevelopmental follow-up.
Parents of study infants will be approached again at 2
years CGA, to request a formal neurodevelopmental
assessment (Bayley III). This will replace one of the rou-
tine OP assessments and take place in the home (where
possible). It will be performed by a consultant in paedia-
tric neurodisability.
Blood sampling and processing
PN blood tests: Routine biochemical monitoring will take
place in accordance with LWH PN guidelines (Appendix
1, section 2.1.4). All blood samples will be processed
according to standard practice and sent to the laboratories
at the Royal Liverpool Children’s Hospital (Alder Hey).
Table 2 Daily flow chart summarising PN administration (maximum possible) and data collection
PN administration (macronutrient content) Week Data collection (nutrition)
Age (d) Protein
(g)
Lipid (g) Dextrose; PN
(%)
Dextrose;
Suppl (%)
1 Enteral/IV fluid intake (ICR) U/EBG Bone/LFT TG AA Growth
std max std max std max std max PN type
1 1.8 1.8 1.0 1.0 10 10 10 10 PN ￿￿ ￿
2 1.8 1.8 1.0 1.0 10 10 10 10 Consent & ￿￿ ￿
3 2.4 2.9 1.9 1.9 10 12 10 12 randomise ￿￿ ￿
4 2.4 2.9 1.9 1.9 10 12 10 12 ￿￿ ￿
5 2.8 3.8 2.8 2.8 10 12 10 12 ￿￿
6 2.8 3.8 2.8 2.8 10 12 10 12 SCAMP ￿￿ ￿
7 2.8 3.8 2.8 3.8 10 12 10 12 SCAMP ￿￿ ￿ ￿
PN administration (macronutrient content) Week Data collection (nutrition)
Age (d) Protein (g) Lipid (g) Dextrose; PN
(%)
Dextrose; Suppl
(%)
2-4 Enteral/IV fluid intake (ICR) U/EBG Bone/LFT TG AA Growth
std max std max std max std max PN type
8 2.8 3.8 2.8 3.8 10 12 10 12 SCAMP ￿￿ ￿
9 2.8 3.8 2.8 3.8 10 12 10 12 SCAMP ￿￿ ￿
10 2.8 3.8 2.8 3.8 10 12 10 12 SCAMP ￿￿
11 2.8 3.8 2.8 3.8 10 12 10 12 SCAMP ￿￿ ￿
12 2.8 3.8 2.8 3.8 10 12 10 12 SCAMP ￿￿
13 2.8 3.8 2.8 3.8 10 12 10 12 SCAMP ￿￿ ￿
14 2.8 3.8 2.8 3.8 10 12 10 12 SCAMP ￿￿ ￿ ￿
Legend: Daily flow chart summary of SCAMP nutrition study protocol including consent, randomisation, PN administration and data collection. Week 2 flow chart
is repeated in week 3 and 4 to complete the 28 day intervention period. Day 29: Patient reverts to standard PN (if still on PN). All routine data collection stops
apart from routine weekly growth data which continues until 36 weeks corrected for gestational age.
Abbreviations: stnd: standard PN (scNPN); max: scNPNmax; ICR: intensive care record of daily fluid/nutrient/drug administration; U/E, BG: routine biochemical
monitoring of plasma electrolytes, glucose, lactate and blood gases; Bone/LFT: routine biochemical monitoring of plasma bone and liver biochemistry; TG:
triglyceride levels; AA amino acid levels.
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T h ep r i m a r yo u t c o m eo ft h es t u d yw i l lb ea s s e s s e db y
comparing the groups allocated to scNPN and
scNPNmax.
Sample size
As a m p l es i z eo f7 5( a s s u m i n gas u r v i v a lr a t eo f8 0 %o f
recruited infants) in each group will have 80% power to
detect a difference between the means of the 2 scNPN
groups for the outcome head growth velocity over the first
28 days after birth of 6 mm. This assumes that the com-
mon standard deviation (SD) is 12 mm and analysis is
based on using a two group t-test with a 0.05 two-sided
significance level. The value for the SD is based on data
gathered during a randomised controlled trial of nutrition
on this unit [17] and previous audit (Cooke unpublished
data). This indicated that head growth velocity in the first
28 days was 24 mm/28d (SD12 mm). To maintain “nor-
mal” head growth (following the birth centile) a growth
velocity of approximately 36 mm/28d is required at 24-28
weeks gestation. Head growth between birth and 28 days
is has an approximately linear growth model (based on
normal growth in utero). Thus the power calculation
assumes that scNPN will achieve a mean growth velocity
of 24 mm/28d (based on results from a nutritionally
equivalent PN) and that the study has the power to detect
an improvement in head growth to a mean growth velocity
of ≥30 mm/28days using scNPNmax assuming a common
standard deviation of 12 mm.
Analysis
A data analysis plan will be finalised when two thirds of
participants have been recruited in order to allow the
details of handling missing data to be based on experi-
ence with data collection. All analysis will be performed
after data cleaning has been complete.
Primary analysis
Primary analysis of the data will be by intention to treat,
and will be done for all survivors. In order to test the
hypothesis that the change in head circumference differs
between the two groups while taking account of the clus-
tering arising from multiple pregnancies, the primary
outcome will be assessed using a general linear model.
Secondary analysis to facilitate interpretation of the
primary outcome
a) Developing a non-linear model of early head growth
(if data analysis indicates this is required)
b) Longitudinal joint modelling of head growth and
survival;
c) Longitudinal joint modelling of head growth and
protein/calorie intake
d) per protocol analysis omitting babies that received
PN other than that due under their allocation for more
than 24 hours;
e) exploratory data analysis of how potential con-
founding variables are distributed between the two
intervention groups
Secondary analysis to characterise the trial
E x p l o r a t o r yd a t aa n a l y s i sw i l lb eu s e dt od e s c r i b et h e
relationships between treatment allocation and:
a) growth measures expected to be concordant with
the primary outcomes
b) efficiency of nutrient delivery
c) metabolic tolerance to each regimen
d) issues relating to the delivery of the nutritional
regimens
e) major neonatal morbidity
f) neurodevelopmental outcome at 2 years
Discussion
Safety and adverse event reporting
Adverse events are relatively common in this patient
group due to immaturity and to concomitant disease
processes. Randomisation is essential for a comparison
of safety among those receiving a study intervention
compared to an appropriate comparator group. Routine
clinical monitoring will be used to ensure that biochem-
ical monitoring stays within limits defined within LWH
clinical guidelines. Glucose and triglyceride monitoring
have guidelines in place to allow PN to be adapted if
abnormal levels arise. Abnormal amino acid profiles are
discussed with a biochemist. These levels of PN macro-
nutrients have been used in several previous studies
without safety concerns.
Expected SAEs (Table 3) that are often observed dur-
ing the course of care following birth at less than 30
weeks gestation before 36 PCA will be recorded on the
specific CRF. All deaths or suspected overdoses will be
reported to the Sponsor by the Chief Investigator within
24 hours using the SAE report form. All SAEs and
deaths will be reported to and reviewed by the Sponsor
and DMC at regular intervals throughout the trial. In
order to examine whether the pattern of these events
differs between the treatment groups, the incidence of
these adverse events will be tabulated and presented to
the DMC at intervals defined in the DMC Charter.
Potential suspected unexpected serious adverse reactions
(SUSARs) will be reported to the R & D department at
LWH within 24 hours of the investigator becoming
aware of them. The R&D Department will evaluate
reported events according to severity, causality and
expectedness according to the Sponsor’s Standard Oper-
ating Procedures. SUSARs will be reported to MHRA/
LREC within the statutory time-frames
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Data Monitoring and Ethics Committee (DMEC)
An independent Data Monitoring and Ethics Committee
(DMEC) has been formed. During the period of recruit-
ment, interim summaries of mortality and SAE will be
supplied, in the strictest confidence, to the DMEC by
the trial statistician. The DMEC has confirmed its terms
of reference and frequency of meetings (approximately 6
monthly, depending on recruitment rate) in its first
meeting, before the trial began. In the light of interim
data and emerging evidence from other studies, the
DMEC will inform the Trial Steering Committee if, in
their view, there is proof beyond reasonable doubt that
t h ed a t ai n d i c a t et h a ta n yp a r to ft h ep r o t o c o li si n d i -
cated or contraindicated either for all infants or for a
particular subgroup of trial participants.
Trial Steering Committee (TSC)
A Trial Steering Committee has been formed to super-
vise the conduct of the study. The terms of reference
were agreed in its first meeting (before the trial began).
The TSC will meet (minimum frequency) within
a month of all DMC meetings to consider their
recommendations.
Study Timetable
Recruitment started in October 2009 following final pro-
tocol approval by ethics committee and the Medicines
and Healthcare products Regulatory Agency (MHRA). It
is anticipated recruitment will have completed in April
2012 allowing analysis of the primary outcome to be
completed by December 2012. The last neurodevelop-
mental assessment would be completed in August 2014.
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